The PREMIER study: a multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or …
…, J Sharp, JL Perez, GT Spencer‐Green - … : Official Journal of …, 2006 - Wiley Online Library
Objective To compare the efficacy and safety of adalimumab plus methotrexate (MTX)
versus MTX monotherapy or adalimumab monotherapy in patients with early, aggressive …
versus MTX monotherapy or adalimumab monotherapy in patients with early, aggressive …
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation
…, M Botfield, CL Ordoñez, GT Spencer-Green… - Thorax, 2012 - thorax.bmj.com
Background VX-809, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator,
has been shown to increase the cell surface density of functional F508del-CFTR in vitro. …
has been shown to increase the cell surface density of functional F508del-CFTR in vitro. …
Efficacy, pharmacodynamics, and safety of VX‐702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double‐blind, placebo‐controlled …
…, RS Kauffman, GT Spencer‐Green - Arthritis & …, 2009 - Wiley Online Library
… Spencer-Green prepared the initial draft of the article with the assistance of a medical writer.
Vertex reviewed and approved the content of the article. Its publication was not contingent …
Vertex reviewed and approved the content of the article. Its publication was not contingent …
Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results.
…, MH Schiff, RW Martin, GT Spencer-Green - The Journal of …, 2003 - jrheum.org
OBJECTIVE: Approximately 3% of the US population over the age of 65 years has rheumatoid
arthritis (RA). We compared the safety and efficacy of etanercept (Enbrel) in patients with …
arthritis (RA). We compared the safety and efficacy of etanercept (Enbrel) in patients with …
[HTML][HTML] Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies
G Spencer-Green, D Alter, HG Welch - The American journal of medicine, 1997 - Elsevier
PURPOSE: To determine the sensitivity and specificity of anti-centromere (ACA) and anti-Scl-70
antibodies in systemic sclerosis (SSc). METHODS: Four-hundred ninety-seven English …
antibodies in systemic sclerosis (SSc). METHODS: Four-hundred ninety-seven English …
Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), Raynaud's syndrome and dermatomyositis
HR Maricq, G Spencer-Green, EC LeRoy - The American journal of …, 1976 - Elsevier
Forty-four study patients with scleroderma (systemic sclerosis) (28 patients), Raynaud's
syndrome (13 patients) or dermatomyositis (three patients) were observed for skin capillary …
syndrome (13 patients) or dermatomyositis (three patients) were observed for skin capillary …
Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue.
Vascular permeability factor (VPF, also known as vascular endothelial growth factor or VEGF),
is a potent microvascular permeability enhancing cytokine and a selective mitogen for …
is a potent microvascular permeability enhancing cytokine and a selective mitogen for …
A multicenter study of outcome in systemic lupus erythematosus.
…, DA Albert, EV Hess, G Spencer‐Green… - … : Official Journal of …, 1982 - Wiley Online Library
A retrospective study of factors influencing survival in 1,103 patients with systemic lupus
erythematosus (SLE) was carried out at 9 university centers diverse in geographic, …
erythematosus (SLE) was carried out at 9 university centers diverse in geographic, …
A multicenter study of outcome in systemic lupus erythematosus. ii.
…, DA Albert, EV Hess, G Spencer‐Green… - … : Official Journal of …, 1982 - Wiley Online Library
Causes of death were examined for 1,103 systemic lupus erythematosus patients who were
followed from 1965 to 1978 at 9 centers that participated in the Lupus Survival Study Group. …
followed from 1965 to 1978 at 9 centers that participated in the Lupus Survival Study Group. …
A phase I pharmacokinetics trial comparing PF‐05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis
…, D Thomas, G Spencer‐Green… - British journal of …, 2016 - Wiley Online Library
Aims Pharmacokinetic (PK) similarity was assessed among PF‐05280586 (a proposed
biosimilar) vs. rituximab sourced from the European Union (rituximab‐EU) and the United States (…
biosimilar) vs. rituximab sourced from the European Union (rituximab‐EU) and the United States (…